Considerable interlaboratory variation in PD‐L1 positivity for head and neck squamous cell carcinoma in the Netherlands—A nationwide evaluation study
MA Hempenius, BM Koomen, IAG Deckers… - …, 2024 - Wiley Online Library
Aims Patients with recurrent or metastatic head and neck squamous cell carcinoma
(HNSCC) are eligible for first‐line immune checkpoint inhibition if their tumour is positive for …
(HNSCC) are eligible for first‐line immune checkpoint inhibition if their tumour is positive for …